BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Completed

Conditions: Advanced Cutaneous Melanoma

First Posted Date: 2012-01-19

Last Posted Date: 2021-12-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1411

Registration Number: NCT01511913

Locations: 🇺🇸
Mid Ohio Onc/Hem, Inc, Columbus, Ohio, United States
🇬🇷
Local Institutio, Alexandroupolis, Greece
🇬🇷
Local institution, Goudi, Athens, Greece

and more 1 locations

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: BMS-790052 (Daclatasvir)
Drug: BMS-650032 (Asunaprevir)

First Posted Date: 2011-12-23

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 224

Registration Number: NCT01497834

Locations: 🇯🇵
Local Institution, Chuo-shi, Yamanashi, Japan

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Telaprevir
Drug: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2011-12-15

Last Posted Date: 2016-06-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 605

Registration Number: NCT01492426

Locations: 🇺🇸
The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸
Atlanta Medical Center, Atlanta, Georgia, United States
🇺🇸
Medical Associates Research Group, San Diego, California, United States

and more 23 locations

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Completed

Conditions: Hepatitis C

Interventions: Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)

First Posted Date: 2011-12-15

Last Posted Date: 2019-11-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1850

Registration Number: NCT01492504

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
Nashville Medical Research Institute, Nashville, Tennessee, United States

and more 60 locations

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: BMS-241027
Drug: Placebo matching BMS-241027

First Posted Date: 2011-12-15

Last Posted Date: 2014-07-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT01492374

Locations: 🇺🇸
Associated Neurologists Of Southern Connecticut, P.C., Fairfield, Connecticut, United States
🇺🇸
Palm Beach Neurological Center Advanced Research Consultants, Palm Beach Gardens, Florida, United States
🇺🇸
Compass Research, Llc, Orlando, Florida, United States

and more 12 locations

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Biological: BMS-982470 (recombinant interleukin-21)
Biological: Ipilimumab

First Posted Date: 2011-12-09

Last Posted Date: 2014-08-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 42

Registration Number: NCT01489059

Locations: 🇺🇸
Oncology Research Associates, Pllc D/B/A, Scottsdale, Arizona, United States
🇺🇸
Ucla Hematology/Oncology., Los Angeles, California, United States
🇺🇸
Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 6 locations

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Phase 2

Terminated

Conditions: HIV-1 Infection

Interventions: Drug: BMS-986001
Drug: Placebo matching with BMS-986001
Drug: Lamivudine
Drug: Tenofovir
Drug: Efavirenz

First Posted Date: 2011-12-09

Last Posted Date: 2016-04-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 297

Registration Number: NCT01489046

Locations: 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇹🇭
Local Institution, Nontaburi, Thailand

and more 12 locations

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Biological: Elotuzumab
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2011-11-23

Last Posted Date: 2018-05-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 185

Registration Number: NCT01478048

Locations: 🇺🇸
Cancer Center Of Acadiana, Lafayette, Louisiana, United States
🇺🇸
Medical University Of South Carolina, Charleston, South Carolina, United States
🇺🇸
Ucla Department Of Medicine, Los Angeles, California, United States

and more 28 locations

Patterns of Use of Belatacept: Analysis of Data From the Collaborative Transplant Study

Completed

Conditions: Transplantation, Organ

First Posted Date: 2011-11-22

Last Posted Date: 2018-05-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 72392

Registration Number: NCT01476943

Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: INX-08189 50 mg
Drug: 240 mg verapamil HCL ER
Drug: 50 mg dose of INX-08189 and 240 mg verapamil HCL ER

First Posted Date: 2011-11-16

Last Posted Date: 2012-06-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT01471704

Locations: 🇺🇸
Prism Research, LLC, St Paul, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy